TNG462 + Pembrolizumab
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 33/100
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Locally Advanced Solid Tumor
Conditions
Locally Advanced Solid Tumor
Trial Timeline
May 26, 2023 → Sep 1, 2026
NCT ID
NCT05732831About TNG462 + Pembrolizumab
TNG462 + Pembrolizumab is a phase 1/2 stage product being developed by Tango Therapeutics for Locally Advanced Solid Tumor. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05732831. Target conditions include Locally Advanced Solid Tumor.
What happened to similar drugs?
5 of 20 similar drugs in Locally Advanced Solid Tumor were approved
Approved (5) Terminated (1) Active (14)
Hype Score Breakdown
Clinical
9
Activity
15
Company
9
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05732831 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Locally Advanced Solid Tumor